Navigation Links
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Date:6/4/2010

the disease.

The ZODIAC, (Zactima in cOmbination with Docetaxel In non-smAll cell lung Cancer) study enrolled 1,391 patients with non-small cell lung cancer from 198 centers between May 2006 and April 2008; all had received chemotherapy previously. Participants were randomized to receive either docetaxel and placebo, or docetaxel and vandetanib. The median follow-up was 12.8 months and the study's primary endpoint was progression-free survival.

Patients in the combination arm had a 21 percent reduction in disease progression, compared to those who received docetaxel alone (hazard ratio, .79), and their median progression-free survival was 17.3 weeks. In contrast, the median progression-free survival in the control arm was 14 weeks. While it trended positive, however, there was no statistical difference in overall survival in the two groups. There was a statistically significant improvement in the time to worsening of symptoms (hazard ratio, .77).

"Obviously, our ultimate goal is to always improve survival for our patients, however the improved time to progression with less of a number of significant effects is important," said Herbst. "This is certainly a drug, where, if we could identify molecular parameters that predict response, we could some day take a group that's receiving docetaxel and vandetanib and see them do even better. We're not there yet, but hopefully this study will serve as the foundation for the merger of personalization and discovery with the now-proven safety and efficacy."

In terms of side effects, patients who received vandetanib experienced more diarrhea, rash and neutropenia. However, they experienced less of the significant side effects - nausea, vomiting, and anemia - than those who received docetaxel alone. The lack of significant side effects is quite striking, said Herbst, because other agents that target VEGF are associated with increased toxicity, including pulmonary bleeding.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Spending time in nature makes people feel more alive, study shows
2. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
3. Prostate Cancer Vaccine Shows Few Side Effects
4. Brief Exercise Reduces Impact of Stress on Cell Aging, UCSF Study Shows
5. Landmark Clinical Trial Shows Surgery and Stenting Equally Safe and Effective at Preventing Stroke
6. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
7. Gene Therapy Shows Promise for Muscular Dystrophy
8. CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
9. Fat in Males, Females Differs Genetically, Mouse Study Shows
10. Social Media Driving Leads & Sales, New Report Shows
11. Drug in new class of targeted therapies shows early promise against blood-related cancers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 (HealthDay ... is nothing new. The first kidney transplant took place ... and the first human heart transplant in 1967. By 2010, ... face. One major organ still eludes the transplant surgeon, ... U.S. scientists has its way, that dream may become reality, ...
(Date:10/31/2014)... year, people across the United States spend an estimated ... which costs $522 billion, according to new research. ... the time and wages that caregivers give up every ... daily activities. The study authors said the significant financial ... flexibility policies. "Our findings provide a new and ...
(Date:10/30/2014)... Einstein College of Medicine of Yeshiva ... their latest aging research at the Gerontological Society ... include the identification of a genotype that can ... the cellular biology of aging. GSA 2014 will ... "Einstein-Montefiore has distinguished itself in a range of ...
(Date:10/30/2014)... research group at the DFG Research Center for Regenerative ... Dresden (CRTD) demonstrated for the first time the in ... three dimensions from mouse embryonic stem cells. Correct spatial ... the dorsal/ventral axis was observed., This study has been ... Cell Reports " on 30.10.2014 ., For many years ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2Health News:Facebook Websites In Thirty-Seconds 2
... clarify the disease,s connection to obesity , , TUESDAY, Dec. 30 ... their blood appear to be more likely to develop breast ... might be the link between obesity and breast cancer, say ... York City. High insulin levels have already been associated with ...
... variant had cancer as well as idiopathic pulmonary fibrosis, study ... mutation in a gene previously found to help protect the ... and some inherited cases of a lethal lung disease affecting ... in the SFTPA2 gene have been found in ...
... resident Gary Balady, MD, a cardiologist in the Division ... of medicine at the Boston University School of Medicine ... by Castle Connolly Medical Ltd. , The America,s Top ... is a trusted and authoritative resource for identifying top ...
... cruciate ligament (ACL) reconstruction can be difficult, but a review of ... edition of Sports Health: A Multidisciplinary Approach highlights how the use ... issues. , ... Rosemont, IL (Vocus) December 30, 2008 ...
... Treat Diseases (HTDS) www.htdsmedical.com (temporary site up ... it has registered with Pink Sheets for its back ... information including updating last 2 years financial statements. The ... a "Yield" rank from the current "STOP" no information ...
... with fish oil can improve health and cholesterol levels, however, new ... Approach highlights the effects of the omega fish oil on professional ... ... -- Researchers have firmly established that supplementing a diet with fish ...
Cached Medicine News:Health News:High Insulin May Boost Odds of Breast Cancer 2Health News:Gene Mutation Tied to Inherited Fatal Lung Disease 2Health News:BMC, Boston University School of Medicine cardiologist named 1 of America's Top Doctors 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 2Health News:Adding Eccentric Resistance Training Improves Muscle Strength Following ACL Surgery 3Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 2Health News:Study Shows Fish Oils Dramatically Improve Cholesterol Levels in Professional Football Players 3
(Date:10/31/2014)... announces the list of stocks featured in the Analyst Blog. Every ... events impacting stocks and the financial markets. Stocks recently featured in ... Report ), Celgene (Nasdaq: CELG - Free Report ... ), Market Vectors Biotech ETF (AMEX: BBH - ... XBI - Free Report ). Today, Zacks is ...
(Date:10/31/2014)... 31, 2014 /CNW Telbec/ - Ergoresearch Ltd ... plan, for accelerated growth in terms of sales and ... reached $17,862,341. Net income amounted to $1,230,153. The EBITDA ... first time in the Company,s history. With ... the forces of its subsidiaries, merging in September 2014 ...
(Date:10/31/2014)... -- Though therapies are in their nascent phase, sales ... annual increase of 16.2% over the 2010-2020 period, reaching ... to Kalorama Information,s report, Stem Cell Therapeutics Markets ... have gained or are expected to gain approval from ... ever more complicated conditions, stem cell therapies hold the ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Report: Stem Cell Technologies Market Growing 2
... 20 Santaris Pharma announced today that,the fourth ... In the USA,several patients with cancer have now ... jointly developed by Santaris Pharma and Enzon,Pharmaceuticals. The ... Pharma­ceutical,s Investigational New Drug (IND) application,for the use ...
... Expands Overseas TBI TrialCOSTA MESA, Calif., March 19 ... that the company has received a letter from the ... forward" as a basis to resume clinical studies of ... therapeutic oxygen carrier.The letter was in response to the ...
Cached Medicine Technology:Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 2Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: